ホーム 計算ツール
代理店ログイン

Ephrin Receptor

Eph receptors (Ephs, after erythropoietin-producing human hepatocellular receptors) are a group of receptors that are activated in response to binding with Eph receptor-interacting proteins (Ephrins). Ephs form the largest known subfamily of receptor tyrosine kinases (RTKs). Both Eph receptors and their corresponding ephrin ligands are membrane-bound proteins that require direct cell-cell interactions for Eph receptor activation. Eph/ephrin signaling has been implicated in the regulation of a host of processes critical to embryonic development including axon guidance, formation of tissue boundaries, cell migration, and segmentation. Additionally, Eph/ephrin signaling has recently been identified to play a critical role in the maintenance of several processes during adulthood including long-term potentiation, angiogenesis, and stem cell differentiation and cancer.
Cat. No. 製品名 CAS No. Purity Chemical Structure
TQ0166 Tesevatinib 781613-23-8 97.89%
Tesevatinib (XL-647) is an orally available, multi-target tyrosine kinase inhibitor (IC50s: 0.3, 16, 1.5, 8.7, and 1.4 nM for EGFR, ErbB2, KDR, Flt4, and EphB4)....
T6348 NVP-BHG712 940310-85-0 97.96%
NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c...
T5452 Ehp-inhibitor-2 861249-77-6 98.02%
Ehp-inhibitor-2 is an Eph family tyrosine kinase inhibitor targeting Eph receptors.
T9650 AZ12672857 945396-55-4 98.05%
AZ12672857 is an inhibitor of EphB4 with IC50 of 1.3 nM. AZ12672857 inhibits cell proliferation of Src transfected 3T3 cells with IC50 of 2 nM and autophosphoryl...
T4344 ALW-II-41-27 1186206-79-0 98.17%
ALW-II-41-27 (Eph receptor tyrosine kinase inhibitor), an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy.
T2456 Tivozanib 475108-18-0 98.23%
Tivozanib (KRN951) is an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and anti...
T4349 Sitravatinib 1123837-84-2 98.9%
Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Ax...
TP1561 123C4 2034159-30-1 98.94%
123C4 is a novel, potent, and selective agonist of the tyrosine kinase EphA4 receptor.
T73368 UniPR505 2938227-14-4 99.23%
UniPR505 is a potent EphA2 antagonist (IC50: 0.95 µM), a novel 3α-carbamoyloxy derivative with antiangiogenic properties.
T3476 JI-101 900573-88-8 99.41%
JI-101 (CGI-1842) is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor rec...
T5451 Eph inhibitor 2 861249-59-4 99.48%
Eph inhibitor 2 is an Eph family tyrosine kinase inhibitor targeting Eph receptors.
T19487 NVP-BHG712 isomer 2245892-85-5 99.65%
NVP-BHG712 isomer shows conserved non-bonded binding to EPHA2 and EPHB4.
TP1895L1 KYL acetate(676657-00-4 free base) TP1895L1 99.75%
KYL acetate is a EphA4 receptor tyrosine kinase inhibitor (Kd = 0.8 μM). KYL inhibits EphA4-EphrinA5 interactions (IC50 = 6.34 μM).
T67736 ALW-II-49-7 1135219-23-6 99.84%
ALW-II-49-7 is a selective and potent inhibitor of EphB2 kinase with an EC50 value of 40 nM in cell.
T38511 AWL-II-38.3 1135205-94-5 99.87%
AWL-II-38.3 is a highly effective inhibitor of EphA3, a receptor for ephrin-A. It demonstrates potent kinase inhibitory activity against EphA3 and does not show ...
T1448L Dasatinib monohydrate 863127-77-9 99.89%
Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib mon...
T80897 UniPR1447 1809170-68-0 98%
UniPR1447 is a dual antagonist for both EphA2 and EphB2 receptors, exhibiting an IC50 value of 6.6 μM against EphA2-ephrin-A1 binding [1].
T80896 UniPR1449 98%
UniPR1449 is an EphA2 receptor antagonist with a KD of 3.8±2.4 μM, which is significant in cancer pathophysiology [1].
Tesevatinib
TQ0166
Tesevatinib (XL-647) is an orally available, multi-target tyrosine kinase inhibitor (IC50s: 0.3, 16, 1.5, 8.7, and 1.4 nM for EGFR, ErbB2, KDR, Flt4, and EphB4)....
NVP-BHG712
T6348
NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c...
Ehp-inhibitor-2
T5452
Ehp-inhibitor-2 is an Eph family tyrosine kinase inhibitor targeting Eph receptors.
AZ12672857
T9650
AZ12672857 is an inhibitor of EphB4 with IC50 of 1.3 nM. AZ12672857 inhibits cell proliferation of Src transfected 3T3 cells with IC50 of 2 nM and autophosphoryl...
ALW-II-41-27
T4344
ALW-II-41-27 (Eph receptor tyrosine kinase inhibitor), an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy.
Tivozanib
T2456
Tivozanib (KRN951) is an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and anti...
Sitravatinib
T4349
Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Ax...
123C4
TP1561
123C4 is a novel, potent, and selective agonist of the tyrosine kinase EphA4 receptor.
UniPR505
T73368
UniPR505 is a potent EphA2 antagonist (IC50: 0.95 µM), a novel 3α-carbamoyloxy derivative with antiangiogenic properties.
JI-101
T3476
JI-101 (CGI-1842) is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor rec...
Eph inhibitor 2
T5451
Eph inhibitor 2 is an Eph family tyrosine kinase inhibitor targeting Eph receptors.
NVP-BHG712 isomer
T19487
NVP-BHG712 isomer shows conserved non-bonded binding to EPHA2 and EPHB4.
KYL acetate(676657-00-4 free base)
TP1895L1
KYL acetate is a EphA4 receptor tyrosine kinase inhibitor (Kd = 0.8 μM). KYL inhibits EphA4-EphrinA5 interactions (IC50 = 6.34 μM).
ALW-II-49-7
T67736
ALW-II-49-7 is a selective and potent inhibitor of EphB2 kinase with an EC50 value of 40 nM in cell.
AWL-II-38.3
T38511
AWL-II-38.3 is a highly effective inhibitor of EphA3, a receptor for ephrin-A. It demonstrates potent kinase inhibitory activity against EphA3 and does not show ...
Dasatinib monohydrate
T1448L
Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib mon...
UniPR1447
T80897
UniPR1447 is a dual antagonist for both EphA2 and EphB2 receptors, exhibiting an IC50 value of 6.6 μM against EphA2-ephrin-A1 binding [1].
UniPR1449
T80896
UniPR1449 is an EphA2 receptor antagonist with a KD of 3.8±2.4 μM, which is significant in cancer pathophysiology [1].